Gavi plans to use U.S. cash for malaria, while meeting Kennedy's conditions

The global vaccine group Gavi said on Monday it hopes to use $600 million in soon-to-be-restored U.S. funding to boost malaria and other

vaccination efforts, as it also meets U.S. conditions over phasing out the preservative thimerosal in other vaccines in its portfolio.



The group's board will make the ultimate decision on how the money is used, Gavi said. But malaria is likely a key focus:



Earlier this year, Gavi warned that a $1.9 billion hole in its budget for 2026 to 2030 meant that fewer children were likely to benefit from new malaria vaccines in sub-Saharan Africa, as Reuters reported.